Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis

Simple item page
dc.contributor.authorÖzmen B.
dc.contributor.authorKirmaz C.
dc.contributor.authorAydin K.
dc.contributor.authorKafesciler S.O.
dc.contributor.authorGuclu F.
dc.contributor.authorHekimsoy Z.
dc.date.accessioned2024-07-22T08:22:45Z
dc.date.available2024-07-22T08:22:45Z
dc.date.issued2007
dc.description.abstractBackground. Osteoporosis that is encountered frequently in postmenopausal women, may cause an increased incidence of vertebral and iliac fractures that are associated with excess morbidity. Raloxifene hydrochloride, a selective oestrogen receptor modulator, has been shown to increase bone mineral density and decrease biochemical markers of bone turnover in postmenopausal women, without stimulatory effects on breast or uterus. Levels of proinflammatory cytokines, including IL-6, and TNF-α and TGF-β1 which are important cytokines involved in remodeling, have been evaluated previously in in vitro studies of osteoporosis. However, there seems to be a paucity of in vivo research concerned with changes in these cytokines in osteoporosis. Objective. In this study, we evaluated the effects of raloxifene (Evista®; Lilly Pharmaceutical Co. USA, 60 mg/day) on biochemical bone turnover markers, serum parathyroid hormone, and 25-OH vitamin D, as well as the serum levels of IL-6, TNF-α and TGF-β1, in 22 postmenopausal, osteoporotic women before and after 12 weeks of raloxifene treatment. Methods. Well-matched, postmenopausal, non-osteoporotic control subjects were also enrolled in the study. Serum levels of all the parameters were measured in postmenopausal, osteoporotic women at baseline and end of the study. Results. It was found that serum osteocalcin and parathyroid hormone, and urine deoxypyridinoline levels decreased to normal levels with treatment. Serum 25-OH vitamin D levels after treatment in the patient group were higher than those in the control group. Serum IL-6, TNF-α and TGF-β1 levels did not change significantly with treatment. However, serum levels of IL-6 and TGF-β1 in the patient group after treatment, decreased to levels lower than those found in the control group. Serum TNF-α levels in the patient group before and after treatment, were lower than those in the control group. Conclusion. Raloxifene treatment reduces bone turnover biochemical markers, parathyroid hormone and induces 25-OH vitamin D in postmenopausal women. Moreover, it also affects some serum cytokine levels in the postmenopausal period.
dc.identifier.DOI-ID10.1684/ecn.2007.0097
dc.identifier.issn11485493
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19225
dc.language.isoEnglish
dc.subjectAmino Acids
dc.subjectBiological Markers
dc.subjectBone and Bones
dc.subjectBone Density
dc.subjectBone Remodeling
dc.subjectCalcium
dc.subjectCytokines
dc.subjectFemale
dc.subjectHumans
dc.subjectInterleukin-6
dc.subjectMiddle Aged
dc.subjectOsteocalcin
dc.subjectOsteoporosis, Postmenopausal
dc.subjectParathyroid Hormone
dc.subjectPhosphorus
dc.subjectRaloxifene
dc.subjectSelective Estrogen Receptor Modulators
dc.subjectTransforming Growth Factor beta1
dc.subjectTreatment Outcome
dc.subjectTumor Necrosis Factor-alpha
dc.subjectVitamin D
dc.subjectdeoxypyridinoline
dc.subjectinterleukin 6
dc.subjectosteocalcin
dc.subjectparathyroid hormone
dc.subjectraloxifene
dc.subjectselective estrogen receptor modulator
dc.subjecttransforming growth factor beta1
dc.subjecttumor necrosis factor alpha
dc.subjectvitamin D
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectbone turnover
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectfemale
dc.subjecthuman
dc.subjectin vivo study
dc.subjectparathyroid hormone blood level
dc.subjectpostmenopause osteoporosis
dc.subjectvitamin blood level
dc.titleInfluence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu